Author(s)

Abdou Azaque Zouré^1,2,3, Christelle Nadembega^1,2,4, Djénéba Ouermi^1,2,4, Abdoul Karim Ouattara^1,2,5, Lassina Traoré^1,2,4, Adama Tiemtoré⁶, Olivier Sawadogo⁶, Théodora M. Zohoncon^1,2,4,7, Florencia W. Djigma^1,2,4, Jacques Simpore^1,2,4,7, Cerba-Labiogene Group^1,2

¹Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso.
²Laboratoire de Biologie Moléculaire et de Génétique (LABIOGENE), Université Joseph KI-ZERBO, Ouagadougou, Burkina Faso.
³Institute for Research in Health Sciences (IRSS/CNRST), Ouaga, Burkina Faso.
⁴Department of Biomedical, Hôpital Saint Camille de Ouagadougou (HOSCO), Ouagadougou, Burkina Faso.
⁵Department of Biology, Université Norbert Zongo/Centre Universitaire de Manga, Koudougou, Burkina Faso.
⁶Department of Mathematic, Université de Ouahigouya, Ouahigouya, Burkina Faso.
⁷Faculty of Medicine, University Saint Thomas d’Aquin (USTA), Ouagadougou, Burkina Faso.

Background: The World Health Organization (WHO) has set a goal to eradicate or at least significantly reduce the prevalence the human immunodeficiency virus (HIV), hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) by 2030. The main objective was to provide an evolving overview of the prevalence of HIV, HBV and HCV infection between 2003 and 2022 in Burkina Faso. Methods: It was a retrospective cross-sectional study based on data from 2003 to 2022. The data were collected using information available in the databases of the HOSCO and CERBA laboratories and included all individuals who underwent HIV and/or HBV and/or HCV testing. Data analysis was performed using SPSS version 20.0, EpiInfo 7, and R version 4.1.0. Results were considered statistically significant if p < 0.05. Results: The study recorded 7432 samples and the mean age of the subjects was 27.98 ± 8.50 years. During this period, the respective prevalence of HIV, HBV, and HCV were 4.66% (346/7432), 8.77% (582/6636) and 5.54% (322/5816). However, from 2003 to 2022, there was a significant decrease (P < 0.0001) in HIV-seroprevalence, dropping from 9.60% in 2003 to 2.16% in 2022. On the other hand, there was no significant difference in the prevalence of HBV (P = 0.282) and HCV (P = 0.861). The prevalence of HIV, HBV, and HCV were described by the following linear equations, respectively: $y=-1.75x+12.59;$ $y=-0.24x+10.01$ and $y=-0.11x+6.02$ , with “y” corresponding to prevalence and “x” to the years. Conclusion: Burkina Faso needs to rigorously apply prevention and control strategies recommended by the WHO by 2030.

HIV, Viral Hepatitis B and C, WHO’s 2030 Goal, Burkina Faso

Zouré, A. , Nadembega, C. , Ouermi, D. , Ouattara, A. , Traoré, L. , Tiemtoré, A. , Sawadogo, O. , Zohoncon, T. , Djigma, F. , Simpore, J. and Group, C. (2024) State of the HIV, Hepatitis B and C Virus Pandemic from 2003 to 2022 in Burkina Faso: Evolution of Prevalence Trends and Strategic Recommendations to Achieve the WHO’s Goal for Their Eradication by 2030. Advances in Infectious Diseases, 14, 628-643. doi: 10.4236/aid.2024.143046.